Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 11/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17199593 | 0.85 | MAPK1 (0.59) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL17796561 | 0.83 | MAPT (0.58) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL12332643 | 0.81 | SMN1; SMN2 (0.37) | MAPK1MAPTPOLBSMN1; SMN2LMNA | |
| SCHEMBL24966937 | 0.80 | MAPT (0.47) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL160276 | 0.79 | SMN1; SMN2 (0.51) | ALPLSMN1; SMN2 | |
| SCHEMBL14917715 | 0.78 | MAPK1 (0.34) | MAPK1GAAALPLMAPTSMN1; SMN2 | |
| SCHEMBL175136 | 0.77 | SMN1; SMN2 (0.40) | GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL17187740 | 0.77 | MAPT (0.42) | MAPK1GAAALPLMAPTRAB9A | |
| SCHEMBL29196676 | 0.75 | MAPT (0.68) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL6167693 | 0.74 | DYRK1A (0.35) | MAPK1GAAMAPTPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388568-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025126109-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4551549-A1 | NLRP3 INHIBITORS | Kodiak Sciences Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12275717-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-7425640-B2 | Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents | SCHERING CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20060111411-A1 | Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents | SCHERING CORPORATION | 2006-05-25 | — | — | US | disclosed |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275717-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | MAPK1 1759/4885GAA 2648/4885ALPL 4622/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | MAPK1 176/4885GAA 3836/4885ALPL 3484/4885 |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | MAPK1 1509/4885GAA 76/4885ALPL 3814/4885 |
| US-20250388568-A1 | NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | MAPK1 959/4885GAA 4368/4885ALPL 4863/4885 |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | PRNP, APP, MAPT | MAPK1 2492/4885GAA 615/4885ALPL 4149/4885 |
| US-20060111411-A1 | Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents | GTF3C5, RNGTT, GTF3C1 | MAPK1 2603/4885GAA 1912/4885ALPL 4739/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | MAPK1 320/4885GAA 3444/4885ALPL 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.